ID   PDGFD_HUMAN             Reviewed;         370 AA.
AC   Q9GZP0; A8K9T6; Q9BWV5;
DT   19-SEP-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   07-APR-2021, entry version 156.
DE   RecName: Full=Platelet-derived growth factor D;
DE            Short=PDGF-D;
DE   AltName: Full=Iris-expressed growth factor;
DE   AltName: Full=Spinal cord-derived growth factor B;
DE            Short=SCDGF-B;
DE   Contains:
DE     RecName: Full=Platelet-derived growth factor D, latent form;
DE              Short=PDGFD latent form;
DE   Contains:
DE     RecName: Full=Platelet-derived growth factor D, receptor-binding form;
DE              Short=PDGFD receptor-binding form;
DE   Flags: Precursor;
GN   Name=PDGFD; Synonyms=IEGF, SCDGFB; ORFNames=MSTP036, UNQ1899/PRO4345;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=11162582; DOI=10.1006/bbrc.2000.4187;
RA   Hamada T., Ui-Tei K., Imaki J., Miyata Y.;
RT   "Molecular cloning of SCDGF-B, a novel growth factor homologous to
RT   SCDGF/PDGF-C/fallotein.";
RL   Biochem. Biophys. Res. Commun. 280:733-737(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBUNIT, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=11331881; DOI=10.1038/35074588;
RA   Bergsten E., Uutela M., Li X., Pietras K., Oestman A., Heldin C.-H.,
RA   Alitalo K., Eriksson U.;
RT   "PDGF-D is a specific, protease-activated ligand for the PDGF beta-
RT   receptor.";
RL   Nat. Cell Biol. 3:512-516(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBUNIT, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=11331882; DOI=10.1038/35074593;
RA   LaRochelle W.J., Jeffers M., McDonald W.F., Chillakuru R.A., Giese N.A.,
RA   Lokker N.A., Sullivan C., Boldog F.L., Yang M., Vernet C., Burgess C.E.,
RA   Fernandez E., Deegler L.L., Rittman B., Shimkets J., Shimkets R.A.,
RA   Rothberg J.M., Lichenstein H.S.;
RT   "PDGF D, a novel protease-activated growth factor.";
RL   Nat. Cell Biol. 3:517-521(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Iris;
RX   PubMed=12107412;
RA   Wistow G., Bernstein S.L., Ray S., Wyatt M.K., Behal A., Touchman J.W.,
RA   Bouffard G., Smith D., Peterson K.;
RT   "Expressed sequence tag analysis of adult human iris for the NEIBank
RT   project: steroid-response factors and similarities with retinal pigment
RT   epithelium.";
RL   Mol. Vis. 8:185-195(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Aorta;
RA   Liu B., Liu Y.Q., Wang X.Y., Zhao B., Sheng H., Zhao X.W., Liu S., Xu Y.Y.,
RA   Ye J., Song L., Gao Y., Zhang C.L., Zhang J., Wei Y.J., Cao H.Q., Zhao Y.,
RA   Liu L.S., Ding J.F., Gao R.L., Wu Q.Y., Qiang B.Q., Yuan J.G., Liew C.C.,
RA   Zhao M.S., Hui R.T.;
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 64-369, TISSUE SPECIFICITY, AND DEVELOPMENTAL
RP   STAGE.
RX   PubMed=12427128; DOI=10.1046/j.1523-1755.2002.00662.x;
RA   Changsirikulchai S., Hudkins K.L., Goodpaster T.A., Volpone J.,
RA   Topouzis S., Gilbertson D.G., Alpers C.E.;
RT   "Platelet-derived growth factor-D expression in developing and mature human
RT   kidneys.";
RL   Kidney Int. 62:2043-2054(2002).
RN   [11]
RP   TISSUE SPECIFICITY.
RX   PubMed=11342471; DOI=10.1161/01.cir.103.18.2242;
RA   Uutela M., Lauren J., Bergsten E., Li X., Horelli-Kuitunen N., Eriksson U.,
RA   Alitalo K.;
RT   "Chromosomal location, exon structure, and vascular expression patterns of
RT   the human PDGFC and PDGFC genes.";
RL   Circulation 103:2242-2247(2001).
RN   [12]
RP   TISSUE SPECIFICITY.
RX   PubMed=11980634;
RA   LaRochelle W.J., Jeffers M., Corvalan J.R.F., Jia X.-C., Feng X.,
RA   Vanegas S., Vickroy J.D., Yang X.-D., Chen F., Gazit G., Mayotte J.,
RA   Macaluso J., Rittman B., Wu F., Dhanabal M., Herrmann J., Lichenstein H.S.;
RT   "Platelet-derived growth factor D: tumorigenicity in mice and dysregulated
RT   expression in human cancer.";
RL   Cancer Res. 62:2468-2473(2002).
RN   [13]
RP   TISSUE SPECIFICITY.
RX   PubMed=14514732; DOI=10.1097/01.asn.0000089828.73014.c8;
RA   Taneda S., Hudkins K.L., Topouzis S., Gilbertson D.G., Ophascharoensuk V.,
RA   Truong L., Johnson R.J., Alpers C.E.;
RT   "Obstructive uropathy in mice and humans: potential role for PDGF-D in the
RT   progression of tubulointerstitial injury.";
RL   J. Am. Soc. Nephrol. 14:2544-2555(2003).
RN   [14]
RP   FUNCTION.
RX   PubMed=15271796; DOI=10.1182/blood-2004-04-1485;
RA   Uutela M., Wirzenius M., Paavonen K., Rajantie I., He Y., Karpanen T.,
RA   Lohela M., Wiig H., Salven P., Pajusola K., Eriksson U., Alitalo K.;
RT   "PDGF-D induces macrophage recruitment, increased interstitial pressure,
RT   and blood vessel maturation during angiogenesis.";
RL   Blood 104:3198-3204(2004).
RN   [15]
RP   REVIEW.
RX   PubMed=16279938; DOI=10.1111/j.1742-4658.2005.04989.x;
RA   Reigstad L.J., Varhaug J.E., Lillehaug J.R.;
RT   "Structural and functional specificities of PDGF-C and PDGF-D, the novel
RT   members of the platelet-derived growth factors family.";
RL   FEBS J. 272:5723-5741(2005).
RN   [16]
RP   TISSUE SPECIFICITY, PTM, AND MUTAGENESIS OF ARG-247 AND ARG-249.
RX   PubMed=15988036; DOI=10.1128/mcb.25.14.6279-6288.2005;
RA   Ustach C.V., Kim H.-R.C.;
RT   "Platelet-derived growth factor D is activated by urokinase plasminogen
RT   activator in prostate carcinoma cells.";
RL   Mol. Cell. Biol. 25:6279-6288(2005).
RN   [17]
RP   REVIEW.
RX   PubMed=20434526; DOI=10.1016/j.bbcan.2010.04.003;
RA   Wang Z., Ahmad A., Li Y., Kong D., Azmi A.S., Banerjee S., Sarkar F.H.;
RT   "Emerging roles of PDGF-D signaling pathway in tumor development and
RT   progression.";
RL   Biochim. Biophys. Acta 1806:122-130(2010).
RN   [18]
RP   VARIANT [LARGE SCALE ANALYSIS] TYR-202.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Growth factor that plays an essential role in the regulation
CC       of embryonic development, cell proliferation, cell migration, survival
CC       and chemotaxis. Potent mitogen for cells of mesenchymal origin. Plays
CC       an important role in wound healing. Induces macrophage recruitment,
CC       increased interstitial pressure, and blood vessel maturation during
CC       angiogenesis. Can initiate events that lead to a mesangial
CC       proliferative glomerulonephritis, including influx of monocytes and
CC       macrophages and production of extracellular matrix (By similarity).
CC       {ECO:0000250, ECO:0000269|PubMed:11331881,
CC       ECO:0000269|PubMed:15271796}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Interacts with PDGFRB homodimers,
CC       and with heterodimers formed by PDGFRA and PDGFRB.
CC       {ECO:0000269|PubMed:11331881, ECO:0000269|PubMed:11331882}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:11331882}.
CC       Note=Released by platelets upon wounding.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Long, SCDGF-B-L;
CC         IsoId=Q9GZP0-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short, SCDGF-B-S;
CC         IsoId=Q9GZP0-2; Sequence=VSP_020615;
CC   -!- TISSUE SPECIFICITY: Expressed at high levels in the heart, pancreas,
CC       adrenal gland and ovary and at low levels in placenta, liver, kidney,
CC       prostate, testis, small intestine, spleen and colon. In the kidney,
CC       expressed by the visceral epithelial cells of the glomeruli. A
CC       widespread expression is also seen in the medial smooth muscle cells of
CC       arteries and arterioles, as well as in smooth muscle cells of vasa
CC       rectae in the medullary area. Expressed in the adventitial connective
CC       tissue surrounding the suprarenal artery. In chronic obstructive
CC       nephropathy, a persistent expression is seen in glomerular visceral
CC       epithelial cells and vascular smooth muscle cells, as well as de novo
CC       expression by periglomerular interstitial cells and by some neointimal
CC       cells of atherosclerotic vessels. Expression in normal prostate is seen
CC       preferentially in the mesenchyme of the gland while expression is
CC       increased and more profuse in prostate carcinoma. Expressed in many
CC       ovarian, lung, renal and brain cancer-derived cell lines.
CC       {ECO:0000269|PubMed:11331881, ECO:0000269|PubMed:11331882,
CC       ECO:0000269|PubMed:11342471, ECO:0000269|PubMed:11980634,
CC       ECO:0000269|PubMed:12427128, ECO:0000269|PubMed:14514732,
CC       ECO:0000269|PubMed:15988036}.
CC   -!- DEVELOPMENTAL STAGE: Not detectable in the earliest stages of
CC       glomerulogenesis, and not detected in the metanephric blastema or
CC       surrounding cortical interstitial cells. In later stages of
CC       glomerulogenesis, localized to epithelial cells transitioning from the
CC       early developing nephrons of the comma- and S-shaped stages to the
CC       visceral epithelial cells of differentiated glomeruli. In the
CC       developing pelvis, expressed at the basement membrane of immature
CC       collecting ducts and by presumptive fibroblastic cells in the
CC       interstitium. {ECO:0000269|PubMed:12427128}.
CC   -!- PTM: Activated by proteolytic cleavage. Proteolytic removal of the N-
CC       terminal CUB domain releasing the core domain is necessary for
CC       unmasking the receptor-binding epitopes of the core domain. Cleavage
CC       after Arg-247 or Arg-249 by urokinase plasminogen activator gives rise
CC       to the active form.
CC   -!- SIMILARITY: Belongs to the PDGF/VEGF growth factor family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB033832; BAB18903.1; -; mRNA.
DR   EMBL; AF336376; AAK56136.1; -; mRNA.
DR   EMBL; AF335584; AAK38840.1; -; mRNA.
DR   EMBL; AY027517; AAK20081.1; -; mRNA.
DR   EMBL; AY027518; AAK20082.1; -; mRNA.
DR   EMBL; AF113216; AAG39287.1; -; mRNA.
DR   EMBL; AY359116; AAQ89474.1; -; mRNA.
DR   EMBL; AK292801; BAF85490.1; -; mRNA.
DR   EMBL; CH471065; EAW67045.1; -; Genomic_DNA.
DR   EMBL; BC030645; AAH30645.1; -; mRNA.
DR   CCDS; CCDS41703.1; -. [Q9GZP0-1]
DR   CCDS; CCDS8326.1; -. [Q9GZP0-2]
DR   PIR; JC7591; JC7591.
DR   RefSeq; NP_079484.1; NM_025208.4. [Q9GZP0-1]
DR   RefSeq; NP_149126.1; NM_033135.3. [Q9GZP0-2]
DR   SMR; Q9GZP0; -.
DR   BioGRID; 123223; 22.
DR   ComplexPortal; CPX-2880; Platelet-derived growth factor DD complex.
DR   ComplexPortal; CPX-2889; PDGF receptor beta - PDGF-DD complex.
DR   ComplexPortal; CPX-2890; PDGF receptor alpha-beta - PDGF-DD complex.
DR   IntAct; Q9GZP0; 19.
DR   STRING; 9606.ENSP00000376865; -.
DR   DrugBank; DB05139; CR002.
DR   DrugBank; DB05465; Tandutinib.
DR   GlyGen; Q9GZP0; 5 sites, 3 O-linked glycans (4 sites).
DR   iPTMnet; Q9GZP0; -.
DR   PhosphoSitePlus; Q9GZP0; -.
DR   BioMuta; PDGFD; -.
DR   DMDM; 74717921; -.
DR   MassIVE; Q9GZP0; -.
DR   PaxDb; Q9GZP0; -.
DR   PeptideAtlas; Q9GZP0; -.
DR   PRIDE; Q9GZP0; -.
DR   ProteomicsDB; 80102; -. [Q9GZP0-1]
DR   ProteomicsDB; 80103; -. [Q9GZP0-2]
DR   Antibodypedia; 31835; 279 antibodies.
DR   DNASU; 80310; -.
DR   Ensembl; ENST00000302251; ENSP00000302193; ENSG00000170962. [Q9GZP0-2]
DR   Ensembl; ENST00000393158; ENSP00000376865; ENSG00000170962. [Q9GZP0-1]
DR   GeneID; 80310; -.
DR   KEGG; hsa:80310; -.
DR   UCSC; uc001php.4; human. [Q9GZP0-1]
DR   CTD; 80310; -.
DR   DisGeNET; 80310; -.
DR   GeneCards; PDGFD; -.
DR   HGNC; HGNC:30620; PDGFD.
DR   HPA; ENSG00000170962; Tissue enhanced (adrenal).
DR   MIM; 609673; gene.
DR   neXtProt; NX_Q9GZP0; -.
DR   OpenTargets; ENSG00000170962; -.
DR   PharmGKB; PA134892327; -.
DR   VEuPathDB; HostDB:ENSG00000170962.12; -.
DR   eggNOG; ENOG502QPQY; Eukaryota.
DR   GeneTree; ENSGT00940000159575; -.
DR   HOGENOM; CLU_037859_1_0_1; -.
DR   InParanoid; Q9GZP0; -.
DR   OMA; FVYTLVC; -.
DR   OrthoDB; 962163at2759; -.
DR   PhylomeDB; Q9GZP0; -.
DR   TreeFam; TF332130; -.
DR   PathwayCommons; Q9GZP0; -.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   SignaLink; Q9GZP0; -.
DR   BioGRID-ORCS; 80310; 5 hits in 989 CRISPR screens.
DR   ChiTaRS; PDGFD; human.
DR   GeneWiki; PDGFD; -.
DR   GenomeRNAi; 80310; -.
DR   Pharos; Q9GZP0; Tbio.
DR   PRO; PR:Q9GZP0; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q9GZP0; protein.
DR   Bgee; ENSG00000170962; Expressed in adrenal gland and 213 other tissues.
DR   ExpressionAtlas; Q9GZP0; baseline and differential.
DR   Genevisible; Q9GZP0; HS.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0008083; F:growth factor activity; IEA:UniProtKB-KW.
DR   GO; GO:0070851; F:growth factor receptor binding; IBA:GO_Central.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; IBA:GO_Central.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0007275; P:multicellular organism development; IEA:UniProtKB-KW.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0051781; P:positive regulation of cell division; IEA:UniProtKB-KW.
DR   GO; GO:0030335; P:positive regulation of cell migration; IBA:GO_Central.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IBA:GO_Central.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IBA:GO_Central.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0072126; P:positive regulation of glomerular mesangial cell proliferation; IEA:Ensembl.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IBA:GO_Central.
DR   GO; GO:2000439; P:positive regulation of monocyte extravasation; IEA:Ensembl.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IBA:GO_Central.
DR   GO; GO:0031954; P:positive regulation of protein autophosphorylation; IBA:GO_Central.
DR   GO; GO:0071673; P:positive regulation of smooth muscle cell chemotaxis; IEA:Ensembl.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   CDD; cd00041; CUB; 1.
DR   CDD; cd00135; PDGF; 1.
DR   Gene3D; 2.10.90.10; -; 1.
DR   Gene3D; 2.60.120.290; -; 1.
DR   InterPro; IPR000859; CUB_dom.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR000072; PDGF/VEGF_dom.
DR   InterPro; IPR027123; PDGFD.
DR   InterPro; IPR035914; Sperma_CUB_dom_sf.
DR   PANTHER; PTHR11633:SF4; PTHR11633:SF4; 1.
DR   Pfam; PF00431; CUB; 1.
DR   Pfam; PF00341; PDGF; 1.
DR   SMART; SM00042; CUB; 1.
DR   SUPFAM; SSF49854; SSF49854; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS01180; CUB; 1.
DR   PROSITE; PS50278; PDGF_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cleavage on pair of basic residues;
KW   Developmental protein; Disulfide bond; Glycoprotein; Growth factor;
KW   Mitogen; Proto-oncogene; Reference proteome; Secreted; Signal.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000255"
FT   CHAIN           19..370
FT                   /note="Platelet-derived growth factor D, latent form"
FT                   /id="PRO_0000250188"
FT   CHAIN           250..370
FT                   /note="Platelet-derived growth factor D, receptor-binding
FT                   form"
FT                   /evidence="ECO:0000255"
FT                   /id="PRO_0000250189"
FT   DOMAIN          52..170
FT                   /note="CUB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00059"
FT   SITE            247..248
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000255"
FT   SITE            249..250
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        276
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        109..131
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00059"
FT   DISULFID        296
FT                   /note="Interchain"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00059"
FT   DISULFID        302..360
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00059"
FT   DISULFID        306..362
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00059"
FT   VAR_SEQ         42..47
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11162582,
FT                   ECO:0000303|PubMed:12107412, ECO:0000303|PubMed:12975309,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_020615"
FT   VARIANT         190
FT                   /note="I -> V (in dbSNP:rs35045740)"
FT                   /id="VAR_051563"
FT   VARIANT         202
FT                   /note="D -> Y (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036418"
FT   MUTAGEN         247
FT                   /note="R->A: Abolishes cleavage into active form; when
FT                   associated with A-249."
FT                   /evidence="ECO:0000269|PubMed:15988036"
FT   MUTAGEN         249
FT                   /note="R->A: Abolishes cleavage into active form; when
FT                   associated with A-247."
FT                   /evidence="ECO:0000269|PubMed:15988036"
SQ   SEQUENCE   370 AA;  42848 MW;  D387F485E7BB7674 CRC64;
     MHRLIFVYTL ICANFCSCRD TSATPQSASI KALRNANLRR DESNHLTDLY RRDETIQVKG
     NGYVQSPRFP NSYPRNLLLT WRLHSQENTR IQLVFDNQFG LEEAENDICR YDFVEVEDIS
     ETSTIIRGRW CGHKEVPPRI KSRTNQIKIT FKSDDYFVAK PGFKIYYSLL EDFQPAAASE
     TNWESVTSSI SGVSYNSPSV TDPTLIADAL DKKIAEFDTV EDLLKYFNPE SWQEDLENMY
     LDTPRYRGRS YHDRKSKVDL DRLNDDAKRY SCTPRNYSVN IREELKLANV VFFPRCLLVQ
     RCGGNCGCGT VNWRSCTCNS GKTVKKYHEV LQFEPGHIKR RGRAKTMALV DIQLDHHERC
     DCICSSRPPR
//
